Abdul Mannan: Recognition and Management of Febrile Non-Haemolytic Transfusion Reactions in Clinical Practice
Abdul Mannan, Consultant Hematologist at Betsi Cadwaladr University Health Board, shared a post on LinkedIn:
“FNHTR is the most common transfusion reaction — but its real danger is that it can mimic the early signs of a haemolytic transfusion reaction (HTR), which is life-threatening.
The hook should create that tension: common but terrifying until proven otherwise.
Fever during a blood transfusion.
Every junior doctor freezes.
Is this dangerous?
Do I stop the blood?
Is my patient haemolysing?
Most of the time? It’s FNHTR.
But you can’t assume that.
Here’s the framework:
What’s happening:
- Recipient antibodies attack donor white cells
- Or cytokines accumulate in the stored bag
- Result: fever ≥38°C or a ≥1°C rise, with chills and rigors
The diagnosis is by exclusion:
- No hypotension
- No respiratory distress
- No haemolysis
If ANY of these are present — think harder.
What to do:
- STOP the transfusion immediately
- Send blood for labs (FBC, DAT, repeat group and screen)
- Give paracetamol
- Only RESTART slowly once you’ve ruled out something serious
Prevention:
- Leucodepletion of blood components
- All UK blood products are now leucodepleted — this has cut FNHTR rates dramatically
The 2023 SHOT report still lists FNHTR as the most reported transfusion complication in the UK.
Common doesn’t mean trivial.
When you stop that bag — you’re not overreacting.
You’re doing exactly the right thing.
What’s the most challenging transfusion reaction you’ve managed?”
Other posts from Abdul Mannan on Hemostasis Today.
-
Jun 29, 2026, 05:20Deepti Sachan: A Global Exchange Shaping the Future of Transfusion Medicine at ISBT 2026
-
Jun 29, 2026, 04:50Scott Cameron: ACC/AHA Guidance on Acute Pulmonary Embolism Management
-
Jun 29, 2026, 03:10Aryabhatta Sadhu: ABO and Rh Incompatibility In Stem Cell Transplantation
-
Jun 29, 2026, 02:41Arun V. J.: ISBT Is Where the Future of Transfusion Medicine Begins
-
Jun 29, 2026, 02:41Manish Raturi: Does Patient Type Matter in Massive Blood Transfusion?
-
Jun 29, 2026, 02:25Hortense Ngegni: From Poster Presentation to Global Connections at ISBT 2026
-
Jun 29, 2026, 01:19Peter Jaworski: Grateful to Win the 2026 Plasma Hero Award at Immune Deficiency Foundation Conference
-
Jun 29, 2026, 01:11Gerrit M. Grosse: Mapping the Landscape of Biomarkers in Post-Stroke Cognitive Impairment
-
Jun 29, 2026, 01:07Katerina Pavenski: Key Insights on Patient Blood Management at ISBT 2026